Yamini S Bynagari-Settipalli1, Ivo Cornelissen1, Daniel Palmer1, Daniel Duong1, Cherry Concengco1, Jerry Ware1, Shaun R Coughlin2. 1. From the Cardiovascular Research Institute, University of California, San Francisco (Y.S.B.-S., I.C., D.P., D.D., C.C., S.R.C.); and Department of Physiology & Biophysics, University of Arkansas for Medical Sciences, Little Rock (J.W.). 2. From the Cardiovascular Research Institute, University of California, San Francisco (Y.S.B.-S., I.C., D.P., D.D., C.C., S.R.C.); and Department of Physiology & Biophysics, University of Arkansas for Medical Sciences, Little Rock (J.W.). shaun.coughlin@ucsf.edu.
Abstract
OBJECTIVE: Current antiplatelet strategies to prevent myocardial infarction and stroke are limited by bleeding risk. A better understanding of the roles of distinct platelet-activating pathways is needed. We determined whether platelet activation by 2 key primary activators, thrombin and collagen, plays distinct, redundant, or interacting roles in tail bleeding and carotid thrombosis in mice. APPROACH AND RESULTS: Platelets from mice deficient for the thrombin receptor protease-activated receptor-4 (Par4) and the collagen receptor glycoprotein VI protein (GPVI) lack responses to thrombin and collagen, respectively. We examined tail bleeding and FeCl3-induced carotid artery occlusion in mice lacking Par4, GPVI, or both. We also examined a series of Par mutants with increasing impairment of thrombin signaling in platelets. Ablation of thrombin signaling alone by Par4 deficiency increased blood loss in the tail bleeding assay and impaired occlusive thrombus formation in the carotid occlusion assay. GPVI deficiency alone had no effect. Superimposing GPVI deficiency on Par4 deficiency markedly increased effect size in both assays. In contrast to complete ablation of thrombin signaling, 9- and 19-fold increases in EC50 for thrombin-induced platelet activation had only modest effects. CONCLUSIONS: The observation that loss of Par4 uncovered large effects of GPVI deficiency implies that Par4 and GPVI made independent, partially redundant contributions to occlusive thrombus formation in the carotid and to hemostatic clot formation in the tail under the experimental conditions examined. At face value, these results suggest that thrombin- and collagen-induced platelet activation can play partially redundant roles, despite important differences in how these agonists are made available to platelets.
OBJECTIVE: Current antiplatelet strategies to prevent myocardial infarction and stroke are limited by bleeding risk. A better understanding of the roles of distinct platelet-activating pathways is needed. We determined whether platelet activation by 2 key primary activators, thrombin and collagen, plays distinct, redundant, or interacting roles in tail bleeding and carotid thrombosis in mice. APPROACH AND RESULTS: Platelets from mice deficient for the thrombin receptor protease-activated receptor-4 (Par4) and the collagen receptor glycoprotein VI protein (GPVI) lack responses to thrombin and collagen, respectively. We examined tail bleeding and FeCl3-induced carotid artery occlusion in mice lacking Par4, GPVI, or both. We also examined a series of Par mutants with increasing impairment of thrombin signaling in platelets. Ablation of thrombin signaling alone by Par4deficiency increased blood loss in the tail bleeding assay and impaired occlusive thrombus formation in the carotid occlusion assay. GPVI deficiency alone had no effect. Superimposing GPVI deficiency on Par4 deficiency markedly increased effect size in both assays. In contrast to complete ablation of thrombin signaling, 9- and 19-fold increases in EC50 for thrombin-induced platelet activation had only modest effects. CONCLUSIONS: The observation that loss of Par4 uncovered large effects of GPVI deficiency implies that Par4 and GPVI made independent, partially redundant contributions to occlusive thrombus formation in the carotid and to hemostatic clot formation in the tail under the experimental conditions examined. At face value, these results suggest that thrombin- and collagen-induced platelet activation can play partially redundant roles, despite important differences in how these agonists are made available to platelets.
Authors: Pierre Mangin; Cindy L Yap; Christelle Nonne; Sharelle A Sturgeon; Isaac Goncalves; Yuping Yuan; Simone M Schoenwaelder; Christine E Wright; Francois Lanza; Shaun P Jackson Journal: Blood Date: 2006-01-03 Impact factor: 22.113
Authors: H D Lewis; J W Davis; D G Archibald; W E Steinke; T C Smitherman; J E Doherty; H W Schnaper; M M LeWinter; E Linares; J M Pouget; S C Sabharwal; E Chesler; H DeMots Journal: N Engl J Med Date: 1983-08-18 Impact factor: 91.245
Authors: Scarlett Gillespie; Paul M Holloway; Felix Becker; Francesca Rauzi; Shantel A Vital; Kirk A Taylor; Karen Y Stokes; Michael Emerson; Felicity N E Gavins Journal: Br J Pharmacol Date: 2018-07-03 Impact factor: 8.739
Authors: Roman Covarrubias; Elena Chepurko; Adam Reynolds; Zachary M Huttinger; Ryan Huttinger; Katherine Stanfill; Debra G Wheeler; Tatiana Novitskaya; Simon C Robson; Karen M Dwyer; Peter J Cowan; Richard J Gumina Journal: Arterioscler Thromb Vasc Biol Date: 2016-07-14 Impact factor: 8.311
Authors: Amanda J Unsworth; Alexander P Bye; Tanya Sage; Renato S Gaspar; Nathan Eaton; Caleb Drew; Alexander Stainer; Neline Kriek; Peter J Volberding; James L Hutchinson; Ryan Riley; Sarah Jones; Stuart J Mundell; Weiguo Cui; Hervé Falet; Jonathan M Gibbins Journal: Haematologica Date: 2021-07-01 Impact factor: 9.941
Authors: Osama M Alshehri; Craig E Hughes; Samantha Montague; Stephanie K Watson; Jon Frampton; Markus Bender; Steve P Watson Journal: Blood Date: 2015-08-17 Impact factor: 22.113